Objective. To assess potential associations for the development of venous thromboembolic events in patients with ANCA-associated vasculitides (AAV).
Introduction
A hallmark of autoimmune disorders is an increased risk of venous thromboembolism (VTE) with a standardized incidence rate of 6.38 in the first year of diagnosis [1] . During the prospective follow-up of the Wegener's Granulomatosis Etanercept Trial (WGET), 8 .9% of the patients with granulomatosis with polyangiitis (GPA; formerly Wegener's granulomatosis) presented with VTE, yielding an incidence of 7.0/100 patient years. In contrast, healthy age-matched individuals had an incidence rate of 0.3/100 patient years. Older age was associated with VTE and the majority of GPA patients had active disease or activity within 2 months before the thromboembolic event [2] , although an elevated prothrombotic risk still persists during remission of ANCA-associated vasculitis (AAV) [3] . Retrospective analyses have reported VTE associations with older age, male gender, previous VTE and stroke with motor deficit in patients with GPA, microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA; formerly ChurgStrauss syndrome) and polyarteritis nodosa (PAN) [4] . A lower frequency of VTE was found in GPA patients with PR3 positivity [5] . We sought to determine novel and validate proposed associations with VTE in patients with GPA and with MPA or renal limited vasculitis (RLV) in a large dataset derived from patients enrolled in European Vasculitis Society (EUVAS) trials.
Methods
Patients EUVAS conducted four randomized controlled trials enrolling patients from 70 hospitals in 15 countries between 1995 and 2002. All trials were conducted according to the 1964 Declaration of Helsinki and subsequent amendments. Patients were diagnosed with GPA, MPA or RLV. These randomized controlled trials recruited patients according to disease severity and extent subgroupings: early systemic vasculitis, one study (the NORAM trial, MTX vs CYC for early systemic disease); generalized vasculitis, two studies (the CYCAZAREM trial, CYC vs AZA for remission in generalized vasculitis; the CYCLOPS trial, daily oral vs pulse CYC for renal vasculitis), and severe disease, one study (the MEPEX trial, methyl prednisolone or plasma exchange for severe renal vasculitis)-for more information see Supplementary Table S1 , available at Rheumatology Online).
Data collection
Data were collected in accordance with the respective trial protocol. Long-term follow-up data were retrieved from participating physicians to determine survival. Respective ethical approval was obtained by national and local ethics committees to collect long-term followup data as has been described before [6] . No separate informed patient consent was necessary to conduct this study. Disease activity was recorded with the BVAS and the Disease Extent Index (DEI). Damage was recorded using the Vasculitis Damage Index. In general, the BVAS reflects disease severity, with life-threatening manifestations yielding a higher score, which may allow a more robust prediction of disease severity, whereas the DEI score is a simplified tool with a uniform scoring system (all manifestations yielding two points, except constitutional symptoms, which yields one point). Baseline demographics (including age, sex and weight), renal function expressed as baseline creatinine and creatinine clearance (estimated glomerular filtration rate was calculated using the modification of diet in renal disease (MDRD) formula), ANCA subtype, GPA or MPA/RLV and co-morbidities such as malignancy, diabetes, chronic heart failure, stroke as well as death and smoking status (never, current, previous) were recorded.
Statistical analysis
Characteristics of patients are presented as mean (S.D.) or %. To identify factors associated with VTE, logistic regression analyses were performed and corrected for multiple testing. All factors having a P < 0.0013 in univariate logistic regression models and clinically significant factors were considered for a multivariate logistic regression analysis adjusted for age, gender, weight, baseline creatinine and CRP. The strength of associations of each variable with VTE is shown as odds ratio (OR) with 95% CI. All statistical analyses were performed with SPSS Statistics v. 21.0 (IBM Corp., Armonk, NY, USA).
Results

Demography
The number of patients included in the analysis was 417 with a median age of 60 (interquartile range (IQR): 4868), 54.4% of whom were male. Diagnosis was GPA in 55% and MPA or RLV in 45%, with PR3 and MPO-ANCA present in 56 and 34%, respectively. At baseline, the median creatinine was 181.0 (IQR: 92.5448.0) mmol/l. Disease activity as assessed by BVAS was 18.0 (IQR: 12.523.0) and using the DEI was 5.0 (IQR: 3.07.0). Concomitant comorbidities consisted of diabetes in 5.5%, chronic heart disease in 7.4% and stroke before enrolment in 4.1% of patients. A majority of patients enrolled were never (54.0%) or former smoker (36.1%). There was no significant difference in follow-up period for patients with VTE compared with those without VTE (P = 0.445). A detailed distribution is shown in Supplementary Table S2, available at Rheumatology Online.
Frequency of VTEs and univariate analyses identifying risk factors
Among the 417 patients, 41 had at least one episode of VTE during follow-up (9.8%, 95% CI: 7.0, 12.7). Median age of patients with VTE at inclusion was 63.0 (IQR: 51.071.0). Patients with VTE had higher baseline creatinine (OR = 1.08, 95% CI: 0.99, 1.18, P = 0.037) compared with those without VTE. No significant difference in the occurrence of VTEs was found between the four studies, although the highest odds ratio was observed in patients www.rheumatology.oxfordjournals.org with severe renal disease (MEPEX, OR = 1.75, 95% CI: 0.86, 3.53, P = 0.120) and the lowest in patients with early systemic disease (NORAM, OR = 0.46, 95% CI: 0.16, 1.32, P = 0.148). In accordance with these findings, there was a trend towards a higher VTE risk in patients undergoing plasma exchange (OR = 2.00, 95% CI: 0.74, 5.41; P = 0.173). After correcting for multiple testing, an increased risk of VTEs could be found for two BVAS items, namely cutaneous involvement (OR = 3.09, 95% CI: 1.59, 6.01; P = 0.001) and gastrointestinal involvement (OR = 5.69, 95% CI: 1.98, 16.31; P = 0.001). At the uncorrected level, a further BVAS item, namely mucous membrane or eye involvement (OR = 2.13, 95% CI: 1.10, 4.41; P = 0.024), was associated with VTE. Univariate analysis demonstrated no significant difference in CRP in patients having VTE or not (OR = 1.02, 95% CI: 0.99, 1.05; P = 0.184). In accordance with this, no significant difference was found for ESR (data not shown). Furthermore, subsequent development of malignancy during follow-up (OR = 2.61, 95% CI: 1.19, 5.71; P = 0.017) was associated with the risk for an onset of VTEs (specific entities are highlighted in Supplementary Table S3 , available at Rheumatology Online). Importantly, a significant association between total BVAS and the development of VTEs was found (OR = 1.05, 95% CI: 1.01, 1.10; P = 0.013), whereas disease activity as assessed by DEI was not associated with VTEs (OR = 1.04, 95% CI: 0.96, 1.12; P = 0.363). Treatment with CYC had an odds ratio of 1.04 and association with VTEs was not significant (95% CI: 0.35, 3.08; P = 0.944). In general, treatment was protocolized. Cumulative glucocorticoid treatment was nonsignificantly higher in patients having VTE [mean (S.D.) 39.8 (18.8) months, median 48 months] compared with those without [37.4 (18.5) months, median 36 months] (P = 0.369) ( Table 1 ). There was no association between VTEs and development of stroke before and during followup as well as diabetes before enrolment, since none of the patients had a thromboembolic event. Other factors analysed did not show an association with the onset of VTE.
Associating factors with VTE occurrence: multivariate analysis In a multivariate model, an increased risk for the development of VTEs was found for cutaneous involvement (OR = 4.83, 95% CI: 1.63, 14.38; P = 0.005) and gastrointestinal manifestation (OR = 6.27, 95% CI: 1.34, 29.37; P = 0.020) as assessed as BVAS items, and baseline creatinine (per 100 mmol/l increase, OR = 1.17, 95% CI: 1.02, 1.35; P = 0.029) and CRP (OR = 1.05, 95% CI: 1.01, 1.09; P = 0.025) after adjustment was made for age, gender and weight (Table 2) .
Discussion
Among the co-morbidities associated with AAV, VTEs have emerged as a frequent finding. The frequency of VTEs in the context of AAV ranged from a standardized incidence ratio of 6.57 (as assessed in a Swedish registry) to a frequency of 12% in a Dutch cohort of patients with severe disease [1, 5] . In our analysis, the frequency of thromboembolic events was 9.8%, which is within the range of previous observations. Analysis of the WGET study reported higher age as a risk to develop a thromboembolic event in GPA [2] , which has previously been described in the general population [7] as well and was corroborated by a retrospective analysis of the French Vasculitis Study Group including patients with GPA, MPA, EGPA and PAN [4] . In contrast, we found no significant association of age with VTEs in AAV. Stassen and coworkers found a lower frequency of VTEs in patients with GPA and those with PR3-ANCA positivity [5] . This protective effect could not be replicated in our analysis. Retrospective analysis of data collected from the French Vasculitis Study Group revealed a higher occurrence rate of VTEs in AAV compared with PAN. In addition to age, they identified male sex, previous VTE and stroke with motor deficit as being associated with a higher VTE risk and lower limb motor neuropathy as being associated with a lower VTE risk [4] . Again, we could not find an association of male gender with risk of VTE in our analysis; moreover none of the patients with stroke before enrolment or during follow-up had a VTE. In general, the association of higher disease activity with the occurrence of VTE is a plausible finding, although this could not be confirmed after correction for multiple testing. We identified novel associations with the onset of VTE: among the BVAS items, cutaneous and gastrointestinal involvement were retained as significant in multivariate analysis, whereas mucous membrane or eye involvement showed association in uncorrected univariate analysis only. The risk for VTEs was 4.83 times higher in patients with cutaneous and 6.27 times higher in individuals with gastrointestinal involvement. These associations were independent of age, gender, weight, baseline creatinine and CRP. Inflammatory markers, such as CRP, have been identified as biomarker of disease activity in AAV [8] . We have found an association of elevated CRP levels and risk of VTE in our study. This is in accordance with a higher risk of developing VTE in the general population having elevated CRP levels at baseline [9] .
Cutaneous vasculitis may provoke local changes leading to hypercoagulability, and gastrointestinal involvement as a severe manifestation was associated with worse outcome in a recent cluster analysis of AAV [10] . Our finding is in accordance with a recent study reporting an association of cutaneous vasculitis and onset of VTE in patients with SLE [11] . Additionally, patients with inflammatory bowel disease are at an 3-fold increased risk of VTE compared with healthy controls, and prophylaxis is recommended in these patients during disease flares, since the increased risk is more prominent while active disease is present [12] . Furthermore, impaired kidney function is a recognized risk factor for VTEs [13] . We found an association of higher baseline creatinine and risk for the development of VTEs. Several influences may make patients with impaired kidney function prone to thrombotic events, including abnormal flow patterns, increase in pro-coagulant and loss of anti-coagulant factors as well as impaired endothelial factors [14] . In uncorrected univariate analysis, our analysis highlighted an association of a classic risk factor, namely malignancy [15] , and onset of VTE in AAV. This is in contrast with earlier reports, which stated that classic associations may play a subsidiary role when assessing the risk of AAV patients [4, 5] . We may speculate that the longer follow-up of patients included in the EUVAS trials depicted the association in our analysis.
The high incidence of VTEs in AAV may be explained by changes in the coagulation pathways. Anti-plasminogen antibodies have been identified in AAV patients (while non-existent or very rare in healthy controls) and were associated with presence of glomerular fibrinoid necrosis, cellular crescents and more severely impaired renal function [16] . An association of anti-plasminogen antibodies with VTE was described in PR3-positive patients before, but total numbers were low and inferences should be drawn with caution [17] . Whether or not anti-plasminogen antibodies may emerge as essential biomarker to predict VTE events in AAV needs to be clarified in future studies. More recently, it was shown that prothrombin fragments and D-dimer levels are elevated during active disease and decreased considerably in remission. However, patients exhibited elevated FVIII as well as von Willebrand factor (VWF) ristocetin cofactor (VWF:RCo) and VWF:antigen during active disease and in remission [18] . This is in line with another recent study that showed persistent elevation of FVIII and tissue factor pathway inhibitor during diverse disease states [3] . Inflammatory mediators and ANCA per se might be able to induce tissue factor and lead to expression in neutrophil extracellular traps and microparticles [19] , while the latter also mediate enhanced thrombin generation associated with clinical thromboembolic events [20] . These findings clearly highlight disease-associated factors, which may make patients prone towards thrombosis and inflammation. Moreover, it is well established that in active AAV several cytokines, growth factors and chemokines are more highly expressed than in remission (including PDGF-AB, circulatory endothelial cells, microparticles of endothelial and platelet origin and IL-8) and some of these are higher in remission compared with healthy controls (including PDGF-AB and IL-8) [8] .
Clearly, several limitations have to be taken into consideration. Firstly, there was no generalized protocol for longterm follow-up of patients recruited into the EUVAS trials. Moreover, information regarding time to event and occurrence of previous VTE events is missing. Analysis of the WGET trial highlighted that thromboembolic events occurred early after study inclusion (median time to VTE 2.07 months) [2] . This needs to be addressed by future studies reporting on VTE risk in AAV. The impact of high cumulative glucocorticoid exposure needs to be addressed in future trials testing low or no oral steroids compared with standard dose (i.e. the PEXIVAS trial). Furthermore, we could not provide data on the potential association between malignancy, VTE and cumulative CYC exposure in our work.
Overall, we found an association of VTE with subsequent development of malignancy, with higher vasculitis activity and among the BVAS items mucous membrane or eye involvement in univariate analysis. After adjustment for age, gender, weight, baseline creatinine and CRP, baseline creatinine, CRP, cutaneous and gastrointestinal involvement were associated with the onset of VTEs. These associations are novel and need to be confirmed in further follow-on studies to prove or disprove the generated hypotheses. More research in the field is necessary to establish markers, which may identify patients at risk and allow tailored, prophylactic anticoagulation for the AAV patient subsets with higher VTE risk.
